Ativan: Clinical Profile and Pharmacology

Ativan, known generically as lorazepam, is one of the most widely utilized and clinically versatile intermediate-acting benzodiazepines in modern medicine. Engineered to modulate central nervous system excitability through the enhancement of gamma-aminobutyric acid neurotransmission, this agent occupies a central role across emergency medicine, neurology, and inpatient psychiatry. Understanding its precise pharmacokinetics, receptor kinetics, therapeutic indications, and adverse event profile is essential for safe and effective clinical practice.

Lorazepam (Ativan)

1. Concise Definition

Ativan is the commercial brand name for lorazepam, a high-potency, intermediate-duration pharmaceutical agent belonging to the 3-hydroxybenzodiazepine chemical class. Pharmacodynamically, it operates as a positive allosteric modulator of the gamma-aminobutyric acid type A (GABA_A receptor) complex, resulting in enhanced inhibitory tone throughout the central nervous system. Its primary pharmacotherapeutic properties include anxiolytic, sedative-hypnotic, anticonvulsant, muscle-relaxant, and anterograde amnestic actions.

In standard therapeutic regimens, Ativan is indicated for the acute management of severe anxiety disorders, the termination of status epilepticus, the alleviation of acute behavioral agitation, the treatment of catatonia, and the symptomatic management of acute alcohol withdrawal syndrome. Because it undergoes direct glucuronidation without relying on hepatic cytochrome P450 oxidative pathways, lorazepam possesses a distinctive pharmacokinetic safety profile among individuals with compromised hepatic function or those receiving multi-drug therapeutic regimens.

2. Etymology & Linguistic Origin

The generic nomenclature lorazepam conforms to the International Nonproprietary Name (INN) schema established for benzodiazepine derivatives. The systematic chemical identifier for the molecule is (RS)-7-chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-2H-1,4-benzodiazepin-2-one. The morpheme benzo- denotes the fused benzene nucleus, while diazepine originates from the chemical identification of an unsaturated seven-membered heterocyclic ring containing two nitrogen atoms (the prefix di- representing two, and az- derived from the French azote, indicating nitrogen).

The distinctive prefix lor- incorporates a contraction designating the ortho-chlorophenyl moiety positioned at carbon 5 of the ring structure, which distinguishes lorazepam chemically from its structural parent, oxazepam. The proprietary designation Ativan was formulated during the mid-twentieth century by Wyeth Laboratories, drawing etymological inspiration from the English term attenuation (derived from the Latin attenuare, meaning to make thin, lessen, or diminish) combined with the conventional pharmaceutical suffix -an, thereby signifying the drug’s capacity to reduce acute psychomotor and autonomic tension.

3. Pronunciation & Grammatical Form

In clinical and pharmacological practice, the term is categorized as follows:

• Pronunciation: The trade name Ativan is pronounced phonetically as /ˈæt.ɪ.væn/ (AT-ih-van). The generic counterpart lorazepam is pronounced as /ləˈræz.ə.pæm/ (lor-AZ-e-pam).
• Grammatical Form: Both Ativan and lorazepam function syntactically as non-count proper and common nouns, respectively. They can serve as direct objects, subjects, or attributive noun adjuncts within clinical terminology (e.g., “lorazepam challenge test,” “Ativan infusion protocol,” or “lorazepam-responsive catatonia”).

4. Detailed Conceptual Explanation

Ativan functions primarily by amplifying the inhibitory neurochemical architecture of the mammalian brain. The human central nervous system maintains an intricate equilibrium between excitatory neurotransmission (principally mediated by L-glutamate) and inhibitory neurotransmission (orchestrated predominantly by gamma-aminobutyric acid). When anxiogenic, epileptic, or agitated states occur, this equilibrium shifts toward excessive, uncoordinated neuronal firing. Lorazepam intervenes not as a direct receptor agonist, but as an allosteric potentiator; it does not activate GABA_A receptors in the total absence of endogenous GABA, but rather markedly potentiates the physiological consequences of endogenous GABA binding.

From a pharmacokinetic perspective, lorazepam exhibits high oral bioavailability, typically exceeding 90 percent. Following oral administration, peak plasma concentrations (C_max) are achieved within 1.5 to 2.5 hours. When administered via the intramuscular route, absorption is rapid, reliable, and complete, reaching maximal therapeutic blood levels within 60 to 90 minutes—an operational attribute that distinguishes it favorably from intramuscular diazepam, which exhibits erratic absorption. Intravenous administration produces an onset of clinical action within 1 to 3 minutes, rendering it a frontline pharmacologic intervention during neurological emergencies such as status epilepticus.

The distribution of lorazepam is characterized by moderate lipid solubility. While it is sufficiently lipophilic to rapidly cross the blood-brain barrier, it is considerably less lipophilic than diazepam or midazolam. Consequently, lorazepam does not undergo rapid systemic redistribution into peripheral adipose tissue stores to the same extent as highly lipophilic agents. This pharmacodynamic feature imparts a clinical paradox: although diazepam possesses a terminal elimination half-life that extends over several days, its duration of central nervous system action following a single intravenous dose is relatively transient (frequently under 30 to 60 minutes) due to rapid redistribution out of the brain. In contrast, lorazepam adheres more tightly to its neuroreceptor targets and demonstrates prolonged central retention, yielding an effective duration of therapeutic anticonvulsant and sedative action spanning 6 to 12 hours despite possessing a much shorter elimination half-life (10 to 20 hours).

The metabolic clearance of lorazepam represents one of its most clinically significant features. Unlike long-acting benzodiazepines (such as diazepam, chlordiazepoxide, and flurazepam) that undergo extensive Phase I oxidative metabolism via hepatic cytochrome P450 enzymes (particularly CYP3A4 and CYP2C19) to yield long-lived pharmacologically active metabolites (e.g., desmethyldiazepam), lorazepam bypasses Phase I functionalization entirely. Instead, it undergoes direct Phase II glucuronidation. Specifically, the 3-hydroxy functional group of the molecule is conjugated with glucuronic acid via hepatic UDP-glucuronosyltransferase isoenzymes (primarily UGT2B7) to generate lorazepam glucuronide, an inert, water-soluble end-product devoid of psychoactive properties. This metabolite is subsequently filtered and excreted by the kidneys. Consequently, lorazepam does not accumulate toxic active intermediates, and its clearance profile remains remarkably stable in the presence of hepatic steatosis, cirrhosis, advancing chronological age, or concomitant medications that inhibit or induce cytochrome P450 cascades.

5. Historical Development

The therapeutic genesis of Ativan is situated within the broader evolution of psychopharmacology during the mid-twentieth century. Following Leo Sternbach’s serendipitous discovery of chlordiazepoxide (Librium) in 1955 and diazepam (Valium) in 1963 at Hoffmann-La Roche, pharmaceutical researchers sought novel benzodiazepine congeners that could offer potent therapeutic efficacy while mitigating the clinical complications associated with extensive tissue accumulation and prolonged oxidative degradation.

Lorazepam was originally synthesized and investigated by chemist D. J. Richards and the research division of Wyeth Laboratories during the 1960s. The compound received its initial patent approvals in 1963 and subsequently underwent rigorous multi-center clinical trials to delineate its pharmacokinetic behavior, anticonvulsant threshold, and anxiolytic efficacy. The United States Food and Drug Administration (FDA) granted formal regulatory approval for the oral formulation of Ativan in 1977, followed shortly thereafter by an injectable formulation for intravenous and intramuscular administration.

During the late 1970s and 1980s, Ativan rapidly transformed acute clinical protocols. Prior to its integration into emergency algorithms, status epilepticus was predominantly treated with intravenous barbiturates (such as phenobarbital) or intravenous diazepam followed by phenytoin infusions. The landmark Veterans Affairs Status Epilepticus Cooperative Study, spearheaded by Treiman and colleagues and published in 1998, provided rigorous empirical validation that established intravenous lorazepam as the superior first-line monotherapy for acute convulsive status epilepticus over phenytoin alone, exhibiting an optimal balance between seizure termination success and hemodynamic stability. Concurrently, in inpatient psychiatry, lorazepam emerged as the international standard of care for acute catatonia and behavioral de-escalation, solidifying its place on the World Health Organization’s Model List of Essential Medicines.

6. Theoretical Foundations & Pharmacological Mechanism

The neurobiological actions of Ativan are grounded in the biophysical architecture of the GABA_A receptor, a member of the Cys-loop superfamily of pentameric ligand-gated ion channels. The classic GABA_A receptor macromolecule is arranged circumferentially around a central water-filled ion pore capable of conducting chloride anions across the neuronal plasma membrane. The most prevalent subunit stoichiometry encountered in the mammalian cerebral cortex, amygdala, and hippocampus consists of two alpha (α), two beta (β), and one gamma (γ) subunit—most commonly organized as α₁β₂γ₂.

Endogenous GABA binds cooperatively at the two extracellular interfaces situated between the α and β subunits. In contrast, Ativan binds selectively to an allosteric pocket located at the interface of the α subunit (α₁, α₂, α₃, or α₅) and the γ₂ subunit. The presence of a histidine residue at specific positions of these α subunits confers sensitivity to benzodiazepines; receptors containing α₄ or α₆ subunits express an arginine residue at this locus, rendering them insensitive to lorazepam.

Upon binding to this allosteric regulatory site, Ativan induces a conformational alteration that structurally stabilizes the receptor in an open-state conformation, markedly augmenting the receptor’s affinity for endogenous GABA molecules. At the single-channel biophysical level, lorazepam increases the frequency of chloride channel opening bursts in response to GABA, differing mechanistically from barbiturates, which primarily prolong the open-state duration of the channel. The resulting influx of extracellular chloride ions down their electrochemical gradient induces intracellular hyperpolarization of the postsynaptic membrane, driving the resting membrane potential further below the action potential threshold.

This widespread neuronal hyperpolarization suppresses spontaneous action potential initiation and dampens signal propagation across critical neural networks:

• Limbic System Suppression: Modulation of α₂– and α₃-containing GABA_A receptors situated within the amygdaloid complex, septal nuclei, and hippocampus dampens hypersensitive threat-detection pathways, producing rapid emotional stabilization and anxiolysis.
• Cortical & Thalamic Inhibition: Activation of densely concentrated α₁ subunits within the cerebral cortex, reticular activating system, and thalamus attenuates thalamocortical transmission, fostering sedation, sleep induction, and electroencephalographic slowing.
• Epileptogenic Dampening: Interruption of synchronous neuronal firing bursts within epileptic foci prevents horizontal propagation across adjacent neocortex and trans-hemispheric recruitment across the corpus callosum.
• Spinal & Brainstem Interneuron Inhibition: Facilitation of glycinergic and GABAergic inhibitory reflex arcs within spinal motor pathways yields myorelaxant and spasmolytic outcomes.

7. Key Components, Dosage Forms & Dimensions

Lorazepam is formulated across several distinct pharmaceutical preparations to accommodate diverse clinical environments:

• Oral Compressed Tablets: Formulated in strengths of 0.5 mg, 1.0 mg, and 2.0 mg, containing inactive pharmaceutical excipients including lactose monohydrate, magnesium stearate, microcrystalline cellulose, and polacrilin potassium. These are primarily indicated for outpatient anxiolysis, premedication, or step-down stabilization.
• Sublingual Tablets: Designed for rapid mucosal dissolution and transmucosal absorption, bypassing hepatic first-pass metabolism partially to provide an accelerated onset of relief during acute panic attacks or severe anticipatory distress.
• Oral Concentrated Solutions: Available as a 2 mg/mL oral liquid formulation, frequently deployed in palliative care, oncology, or geriatric psychiatry where pill dysphagia precludes tablet administration.
• Injectable Parenteral Formulations: Supplied at concentrations of 2 mg/mL and 4 mg/mL in sterile ampules or pre-filled syringes for intramuscular (IM) and intravenous (IV) delivery. Because lorazepam is sparingly soluble in aqueous vehicles, the parenteral formulation requires an organic solvent matrix composed of 80% propylene glycol, 18% polyethylene glycol 400, and 2% benzyl alcohol as an antimicrobial preservative.
• Pharmacological Dimensions: The clinical actions of Ativan fall along five recognized functional axes: anxiolytic potency, hypnotic intensity, anticonvulsant threshold, anterograde amnestic depth, and skeletal muscle relaxation.

8. Examples & Illustrative Cases

The multifaceted utility of Ativan can be illustrated through three distinct clinical vignettes:

Case 1: Emergency Neurological Resuscitation. A 42-year-old male with a history of secondary generalized epilepsy presents via emergency medical services in active convulsive status epilepticus. Continuous generalized tonic-clonic motor activity has persisted for 12 minutes without interval recovery of consciousness. Intravenous access is immediately established. The resuscitation team administers an intravenous bolus of Ativan at 4 mg (titrated at 2 mg/minute). Within 110 seconds of completed infusion, the generalized motor paroxysms terminate, electroencephalographic synchronization aborts, and the patient transitions into a quiet postictal phase, protecting cerebral oxygenation and preventing rhabdomyolysis.

Case 2: Acute Catatonia in Inpatient Psychiatry. A 28-year-old female with bipolar affective disorder is admitted in an akinetic, mute state characterized by profound stupor, waxy flexibility (catalepsy), and refusal of oral hydration. The clinical team initiates a diagnostic and therapeutic “lorazepam challenge.” An intravenous dose of 2 mg of lorazepam is administered while vital signs are tracked continuously. Within 30 minutes, the patient demonstrates a dramatic resolution of catalepsy, begins conversing coherently with nursing staff, and voluntarily consumes liquids, confirming the diagnostic formulation of GABAergic catatonic dysfunction and guiding ongoing maintenance dosing.

Case 3: Symptom-Triggered Alcohol Withdrawal in Hepatic Cirrhosis. A 56-year-old individual with documented Child-Pugh Class B alcoholic cirrhosis presents to the medical step-down unit displaying progressive diaphoresis, autonomic instability, coarse postural tremor, and tactile hallucinations. To avoid the accumulation of long-acting oxidative metabolites associated with chlordiazepoxide or diazepam, the clinician implements a symptom-triggered lorazepam protocol based on the Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar). Doses of 1 to 2 mg of oral lorazepam are administered selectively when CIWA-Ar scores exceed 10. The patient successfully navigates withdrawal delirium over 96 hours without signs of hepatic encephalopathy or protracted oversedation.

9. Measurement & Clinical Assessment

The monitoring and objective evaluation of patients receiving Ativan require validated clinical scales alongside biochemical quantification methods:

From a behavioral and clinical assessment perspective, sedation depth is monitored in acute care environments utilizing the Richmond Agitation-Sedation Scale (RASS), where a score of 0 denotes an alert and calm state, and scores ranging from -1 to -5 designate progressive levels of pharmacologically induced central depression. In alcohol withdrawal management, the CIWA-Ar scoring rubric dictates symptom-triggered titration, minimizing cumulative drug exposure. In catatonia evaluations, the Bush-Francis Catatonia Rating Scale (BFCRS) is systematically scored pre- and post-administration of lorazepam to verify therapeutic responsiveness.

From an analytical and toxicological standpoint, lorazepam levels can be quantified in whole blood, serum, or urine via high-performance liquid chromatography-tandem mass spectrometry (LC-MS/MS) or gas chromatography-mass spectrometry (GC-MS). Standard qualitative urine immunoassay drug screens frequently yield false-negative results for lorazepam because many commercial assays are calibrated to detect oxazepam or nordiazepam conjugates and possess variable cross-reactivity toward lorazepam glucuronide. Clinicians evaluating compliance, diversion, or occult overdose must explicitly order targeted confirmatory mass spectrometry to accurately verify its presence.

10. Applications & Practical Significance

The practical applications of Ativan span several disciplines across contemporary healthcare:

• Status Epilepticus Management: Guidelines from the American Academy of Neurology and the Neurocritical Care Society establish intravenous lorazepam (0.1 mg/kg, up to a typical initial bolus of 4 mg) as the preferred first-line agent for terminating established status epilepticus due to its superior duration of local anticonvulsant activity compared to diazepam.
• Psychiatric Emergency Services: Utilized either as monotherapy or combined synergistically with typical or atypical neuroleptics (such as the classic intramuscular haloperidol-lorazepam combination) to rapidly mitigate severe psychomotor agitation, preventing patient-staff harm and alleviating extreme distress.
• Anesthesiology & Procedural Sedation: Administered preoperatively to attenuate surgical anxiety and exploit its potent anterograde amnestic properties, preventing intraoperative recall and minimizing psychological trauma during uncomfortable bedside procedures (such as awake fiberoptic intubation, bone marrow aspiration, or cardioversion).
• Oncology & Palliative Care: Deployed as a secondary antiemetic for chemotherapy-induced nausea and vomiting (CINV), particularly in resolving refractory or anticipatory conditioned emetic responses mediated by the limbic-vestibular circuitry. Additionally, it relieves terminal dyspnea-associated panic and agitated delirium at end-of-life care stages.

11. Research & Empirical Evidence

Extensive clinical and empirical trials have rigorously defined the therapeutic role of lorazepam:

In the seminal Veterans Affairs Status Epilepticus Cooperative Study (Treiman et al., 1998), 570 patients presenting in overt convulsive status epilepticus were randomized to receive one of four initial treatments: lorazepam, diazepam followed by phenytoin, phenobarbital, or phenytoin alone. Lorazepam achieved rapid, definitive cessation of electrical and motor seizure activity in 64.9% of cases on first attempt, outperforming phenytoin monotherapy (43.6%) and establishing lorazepam as the international gold standard in initial seizure resuscitation.

Subsequent prehospital research expanded these insights. The Rapid Anticonvulsant Medication Prior to Arrival Trial (RAMPART), published by Silbergleit et al. (2012) in the New England Journal of Medicine, investigated whether intramuscular midazolam was non-inferior to intravenous lorazepam when delivered by paramedics in prehospital transport. The trial established that while intravenous lorazepam remains exceptionally efficacious when access is available, intramuscular midazolam achieved faster seizure termination due to the avoidance of delays in obtaining intravenous line placement. This highlighted the operational distinction between drug pharmacokinetics and practical delivery logistics.

Within neuropsychiatry, systematic empirical analyses by Fink, Taylor, and colleagues confirmed that high-potency benzodiazepines, particularly lorazepam, produce full clinical remission in 70% to 80% of acute catatonic episodes. This efficacy stems from rapid normalization of inhibitory tone within orbitofrontal and anterior cingulate networks. These empirical investigations highlight the unique neurochemical position Ativan occupies at the intersection of neurology and acute psychiatric care.

12. Cultural & Cross-Cultural Considerations

Prescribing patterns and societal attitudes regarding Ativan reflect substantial geographic, regulatory, and cultural heterogeneity across the globe:

In North America, Ativan is regulated as a Schedule IV controlled substance under the Controlled Substances Act, subject to strict Prescription Drug Monitoring Programs (PDMPs) to curtail diversion, dependency, and secondary illicit distribution. In the United Kingdom, it is classified as a Class C substance under the Misuse of Drugs Act 1971, with National Institute for Health and Care Excellence (NICE) guidelines recommending that community benzodiazepine prescriptions for anxiety be strictly limited to short-term crises (no longer than 2 to 4 weeks).

Cross-cultural studies indicate notable discrepancies in community utilization rates. In several Southern European and Latin American jurisdictions, benzodiazepine utilization rates historically exceeded those observed in Northern European or East Asian regions. This variance is attributed to differing clinical thresholds for prescribing psychotropic anxiolytics, cultural perceptions surrounding emotional distress, and relative access to psychotherapeutic interventions such as cognitive behavioral therapy (CBT). Furthermore, in regions where resources are constrained, Ativan frequently serves as a frontline agent for a broader spectrum of neurobehavioral disturbances due to the scarcity of comprehensive psychiatric beds and novel atypical psychotropic alternatives.

13. Criticisms, Debates & Limitations

Despite its therapeutic efficacy, Ativan is subject to rigorous clinical debate and well-documented limitations:

Dependence and Neuroadaptation: Continuous administration exceeding two to four weeks systematically triggers physiological neuroadaptation. Chronic occupation of the allosteric binding pocket induces homeostatic downregulation of GABA_A receptor density, functional uncoupling of the allosteric and GABA-binding sites, and compensatory upregulation of glutamatergic AMPA and NMDA receptor systems. Abrupt cessation consequently precipitates a severe, potentially life-threatening withdrawal syndrome characterized by rebound anxiety, diaphoresis, hyperacusis, delirium tremens, and generalized epileptic seizures. Discontinuation mandates a prolonged, highly structured hyperbolic taper.

Cognitive Deficits and Geriatric Vulnerabilities: In older adult populations, Ativan significantly increases the incidence of excessive daytime sedation, psychomotor ataxia, confusion, and fall-related fractures. Consequently, the American Geriatrics Society lists lorazepam and related benzodiazepines as agents to avoid in the elderly according to the updated Beers Criteria. Additionally, long-term retrospective epidemiologic investigations continue to debate the association between extended chronic benzodiazepine exposure and elevated risks for subsequent neurocognitive decline.

Propylene Glycol Toxicity: A critical pharmacology challenge associated specifically with high-dose intravenous lorazepam infusions involves its solvent carrier, propylene glycol. During continuous infusions exceeding 0.1 mg/kg/hour over several days, propylene glycol can accumulate, causing hyperosmolality, high anion-gap metabolic acidosis, acute tubular necrosis, and subsequent renal failure. Clinicians managing intensive care patients receiving sustained Ativan infusions must routinely monitor the serum osmolal gap to avert iatrogenic solvent poisoning.

Respiratory Depression and Opioid Co-Exposure: The FDA maintains a prominent Black Box Warning regarding the concomitant administration of benzodiazepines and opioid analgesics. The simultaneous activation of mu-opioid receptors and GABA_A receptors within the pre-Bötzinger complex of the medulla oblongata blunts the hypercapnic respiratory drive, markedly increasing the likelihood of fatal hypoventilation and hypoxic respiratory arrest.

14. Related Terms & Distinctions

Distinguishing Ativan from adjacent psychopharmacological agents is essential for safe prescribing:

• Lorazepam vs. Diazepam: While diazepam exhibits a faster intravenous onset due to higher lipophilicity, it undergoes rapid tissue redistribution, yielding a shorter central duration of acute seizure control. Diazepam undergoes complex hepatic CYP-mediated oxidation into long-acting active metabolites, whereas lorazepam undergoes direct Phase II glucuronidation, minimizing prolonged accumulation.
• Lorazepam vs. Alprazolam (Xanax): Alprazolam possesses a triazolo ring that confers potent short-acting anxiolysis, but its rapid absorption and rapid clearance are associated with higher rates of inter-dose rebound anxiety and psychological misuse liability compared to the smoother pharmacokinetic arc of lorazepam.
• Lorazepam vs. Clonazepam (Klonopin): Clonazepam has a longer elimination half-life (30 to 50 hours) and lower clearance rate, making it better suited for chronic seizure prophylaxis or baseline anxiety maintenance, whereas Ativan is preferred for acute interventions and rapid titration.
• Lorazepam vs. Midazolam (Versed): Midazolam possesses an imidazole ring conferring water solubility at acidic pH and rapid lipophilicity at physiological pH, rendering it ultra-short-acting. It is ideal for brief procedural sedation, whereas lorazepam provides more durable sedation and seizure control.
• Lorazepam vs. Non-Benzodiazepine Z-Drugs (e.g., Zolpidem): While Z-drugs bind selectively to the α₁ subunit to induce sleep without exerting broad anxiolysis or muscle relaxation, Ativan binds promiscuously across α₁, α₂, α₃, and α₅ subtypes to deliver a wide clinical spectrum of central nervous system effects.

15. Summary & Key Takeaways

Ativan (lorazepam) remains a cornerstone agent in modern clinical medicine. Acting as a positive allosteric modulator of GABA_A receptors, it increases the frequency of chloride channel opening, producing potent central nervous system depression manifested as anxiolysis, sedation, seizure cessation, and muscle relaxation. The drug’s specific pharmacokinetic architecture—characterized by intermediate duration, minimal tissue redistribution, and direct hepatic glucuronidation bypassing the cytochrome P450 enzyme complex—makes it uniquely suited for patients with liver disease, the critically ill, and those facing acute neurological emergencies like status epilepticus.

However, the significant clinical advantages of Ativan must be balanced against its clinical risks: physical tolerance, psychological dependence, life-threatening withdrawal upon abrupt discontinuation, heightened fall risk in older adults, excipient toxicity during high-dose infusions, and fatal respiratory depression when co-administered with opioids. Judicious prescribing requires strict adherence to evidence-based dosing schedules, brief treatment windows for non-emergent indications, and gradual tapering protocols to ensure maximal patient safety.

References

• American Academy of Neurology. (2016). Evidence-based guideline: Treatment of convulsive status epilepticus in children and adults. Neurology, 86(6), 570–578. https://www.aan.com
• By the 2023 American Geriatrics Society Beers Criteria® Update Expert Panel. (2023). American Geriatrics Society 2023 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society, 71(7), 2052–2081. https://doi.org/10.1111/jgs.18372
• Fink, M., & Taylor, M. A. (2003). Catatonia: A Clinician’s Guide to Diagnosis and Treatment. Cambridge University Press. https://doi.org/10.1017/CBO9780511544392
• Silbergleit, R., Durkalski, V., Lowenstein, D., Conwit, R., Pancioli, A., Palesch, Y., Barsan, W., & NETT Investigators. (2012). Intramuscular versus intravenous therapy for prehospital status epilepticus. New England Journal of Medicine, 366(7), 591–600. https://doi.org/10.1056/NEJMoa1107494
• Treiman, D. M., Meyers, P. D., Walton, N. Y., Collins, J. F., Colling, C., Rowan, A. J., Handforth, A., Faught, E., Calabrese, V. P., Uthman, B. M., Ramsay, R. E., & Mamdani, M. B. (1998). A comparison of four treatments for generalized convulsive status epilepticus. New England Journal of Medicine, 339(12), 792–798. https://doi.org/10.1056/NEJM199809173391202